Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.

MLA

Vitale, Maria Giuseppa, et al. “Correlation Between Immune-Related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (MRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-Institutional Retrospective Study.” Clinical Genitourinary Cancer, vol. 18, no. 6, Dec. 2020, pp. 477–88. EBSCOhost, https://doi.org/10.1016/j.clgc.2020.05.010.

APA

Vitale, M. G., Pipitone, S., Venturelli, M., Baldessari, C., Porta, C., Iannuzzi, F., Basso, U., Scagliarini, S., Zucali, P. A., Galli, L., Rossetti, S., Caserta, C., Bracarda, S., Iacovelli, R., Masini, C., Cortellini, A., Di Girolamo, S., Buti, S., Fornarini, G., … Sabbatini, R. (2020). Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 18(6), 477–488. https://doi.org/10.1016/j.clgc.2020.05.010

Chicago

Vitale, Maria Giuseppa, Stefania Pipitone, Marta Venturelli, Cinzia Baldessari, Camillo Porta, Federica Iannuzzi, Umberto Basso, et al. 2020. “Correlation Between Immune-Related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (MRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-Institutional Retrospective Study.” Clinical Genitourinary Cancer 18 (6): 477–88. doi:10.1016/j.clgc.2020.05.010.